678 related articles for article (PubMed ID: 18829721)
1. Daptomycin: rationale and role in the management of skin and soft tissue infections.
Seaton RA
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
[TBL] [Abstract][Full Text] [Related]
2. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.
Stryjewski ME; Chambers HF
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S368-77. PubMed ID: 18462092
[TBL] [Abstract][Full Text] [Related]
3. Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis.
Bliziotis IA; Plessa E; Peppas G; Falagas ME
Ann Pharmacother; 2010 Jan; 44(1):97-106. PubMed ID: 19934396
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry.
Martone WJ; Lamp KC
Curr Med Res Opin; 2006 Dec; 22(12):2337-43. PubMed ID: 17257448
[TBL] [Abstract][Full Text] [Related]
5. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections].
Mathiesen L; Midtvedt T; Solberg CO
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552
[TBL] [Abstract][Full Text] [Related]
6. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy.
Falcone M; Russo A; Pompeo ME; Vena A; Marruncheddu L; Ciccaglioni A; Grossi P; Mancini C; Novelli A; Stefani S; Venditti M
Int J Antimicrob Agents; 2012 Jan; 39(1):64-8. PubMed ID: 22047703
[TBL] [Abstract][Full Text] [Related]
7. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome.
Ruhe JJ; Smith N; Bradsher RW; Menon A
Clin Infect Dis; 2007 Mar; 44(6):777-84. PubMed ID: 17304447
[TBL] [Abstract][Full Text] [Related]
8. The role of antimicrobial therapy for treatment of uncomplicated skin and soft tissue infections from community-acquired methicillin-resistant Staphylococcus aureus in children.
Teng CS; Lo WT; Wang SR; Tseng MH; Chu ML; Wang CC
J Microbiol Immunol Infect; 2009 Aug; 42(4):324-8. PubMed ID: 19949756
[TBL] [Abstract][Full Text] [Related]
9. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
Itani KM; Weigelt J; Li JZ; Duttagupta S
Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
Davis SL; McKinnon PS; Hall LM; Delgado G; Rose W; Wilson RF; Rybak MJ
Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
[TBL] [Abstract][Full Text] [Related]
11. Oral antibiotic treatment for methicillin-resistant Staphylococcus aureus skin and soft tissue infections: review of the literature.
Khawcharoenporn T; Alan T
Hawaii Med J; 2006 Oct; 65(10):290-3. PubMed ID: 17194061
[TBL] [Abstract][Full Text] [Related]
12. Treatment of staphylococcal infections with cyclic lipopeptides.
Eisenstein BI
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():10-6. PubMed ID: 18226085
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical experience with daptomycin.
Hawkey PM
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
[TBL] [Abstract][Full Text] [Related]
14. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy.
Awad SS; Elhabash SI; Lee L; Farrow B; Berger DH
Am J Surg; 2007 Nov; 194(5):606-10. PubMed ID: 17936421
[TBL] [Abstract][Full Text] [Related]
15. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.
French GL
J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic options for treating community-acquired MRSA.
Powell JP; Wenzel RP
Expert Rev Anti Infect Ther; 2008 Jun; 6(3):299-307. PubMed ID: 18588495
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children.
Marcinak JF; Frank AL
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):91-100. PubMed ID: 16441212
[TBL] [Abstract][Full Text] [Related]
18. Daptomycin.
Enoch DA; Bygott JM; Daly ML; Karas JA
J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
[TBL] [Abstract][Full Text] [Related]
19. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis.
Rouse MS; Piper KE; Jacobson M; Jacofsky DJ; Steckelberg JM; Patel R
J Antimicrob Chemother; 2006 Feb; 57(2):301-5. PubMed ID: 16361330
[TBL] [Abstract][Full Text] [Related]
20. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus.
Pallin DJ; Egan DJ; Pelletier AJ; Espinola JA; Hooper DC; Camargo CA
Ann Emerg Med; 2008 Mar; 51(3):291-8. PubMed ID: 18222564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]